Workflow
American Shared Hospital Services(AMS) - 2024 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For fiscal year 2024, total revenue increased by 32.9% to 28.34millioncomparedtofiscalyear2023[2]AdjustedEBITDAforfiscalyear2024increasedby8.928.34 million compared to fiscal year 2023 [2] - Adjusted EBITDA for fiscal year 2024 increased by 8.9% to 8.9 million [2][18] - In Q4 2024, total revenue rose by 59.2% to 9.1millioncomparedtoQ42023[18]Netincomeforfiscalyear2024increasedby2589.1 million compared to Q4 2023 [18] - Net income for fiscal year 2024 increased by 258% to 2.2 million, or 0.33perdilutedshare[17]BusinessLineDataandKeyMetricsChangesRevenuefromdirectpatientservicessegmentforfiscalyear2024was0.33 per diluted share [17] Business Line Data and Key Metrics Changes - Revenue from direct patient services segment for fiscal year 2024 was 12.6 million, a 253% increase from 3.4millioninfiscalyear2023[13][14]Revenuefromtheequipmentleasingsegmentdecreasedby15.63.4 million in fiscal year 2023 [13][14] - Revenue from the equipment leasing segment decreased by 15.6% to 17.8 million in fiscal year 2024 [14] - Gamma Knife revenue decreased by 11.6% to 9.7millionforfiscalyear2024[14]Protonbeamtherapyrevenuedecreasedby1.89.7 million for fiscal year 2024 [14] - Proton beam therapy revenue decreased by 1.8% to 10 million in fiscal year 2024 [15] Market Data and Key Metrics Changes - The company has established its first direct patient services cancer treatment centers in the U.S. with the acquisition of three centers in Rhode Island [11] - The international business segment is expected to see continued growth, particularly in Ecuador and the newly opened center in Puebla, Mexico [9][10] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model [1] - Strategic initiatives include expanding the business footprint in Rhode Island and establishing new treatment centers in Mexico [10][11] - The company aims to enhance operational efficiencies and improve patient care through partnerships with local health systems [7][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy and the ability to navigate industry challenges [39][40] - The company anticipates stronger international growth and increased treatment volumes from new facilities [10][12] - Management highlighted the importance of operational efficiencies and technology investments to support growth initiatives [16][39] Other Important Information - The company ended the year with cash and cash equivalents of 11.3million,downfrom11.3 million, down from 13.8 million at the end of 2023 [25] - Shareholders' equity increased to 25.2million,or25.2 million, or 3.92 per outstanding share, compared to 22.6million,or22.6 million, or 3.59 per outstanding share, at the end of 2023 [25] Q&A Session Summary Question: Benefits of expanding footprint in Rhode Island - Analyst inquired about additional benefits from expanding the footprint in Rhode Island and potential economies of scale with new facilities [30] Response: Synergies from partnerships - Management confirmed that there will be synergies from the relationship with Brown University Health and other local health systems, enhancing cancer care provision in the state [32]